Adherence and persistence with prasugrel following acute coronary syndrome with percutaneous coronary intervention

American Journal of Cardiovascular Drugs

Volumn 13, Issue 4, 2013, Pages 263-271

  Nordstrom, Beth L ^a   Simeone, Jason C ^a   Zhao, Zhenxiang ^b   Molife, Cliff ^b   McCollam, Patrick L ^b   Ye, Xin ^c   Effron, Mark B ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c DAIICHI SANKYO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRASUGREL;

ACUTE CORONARY SYNDROME; ADULT; ANEMIA; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIOMYOPATHY; COHORT ANALYSIS; DEPRESSION; FEMALE; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION;

ACUTE CORONARY SYNDROME; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; RETROSPECTIVE STUDIES; THIOPHENES;

EID: 84880879680     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-013-0028-1     Document Type: Article

References (23)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2-220 2011/12/20.
2. Marshall K. Acute coronary syndrome: diagnosis, risk assessment and management. Nurs Stand. 2011; 25(23):47-57 (quiz 8, 60. Epub 2011/03/23).
3. O'Gara PT, Kushner FG, Ascheim DD, et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362-425 Epub 2012/12/19.
4. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST- elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2012 (Epub 2012/07/18).
5. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011; 124 (23): e574-651 (Epub 2011/11/09).
6. Muntner P, Mann DM, Woodward M, et al. Predictors of low clopidogrel adherence following percutaneous coronary intervention. Am J Cardiol. 2011;108(6):822-7 (Epub 2011/07/12).
7. Zhu B, Zhao Z, McCollam P, et al. Factors associated with clopidogrel use, adherence, and persistence in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Curr Med Res Opin. 2011;27(3):633-41 (Epub 2011/01/19).
8. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004; 364(9444):1519-21 (Epub 2004/10/27).
9. Cannon CP, Acharjee S. Acute coronary syndrome. Cardiovascular events after clopidogrel discontinuation. Rev Cardiovasc Med. 2008; 9(3):212-4 (Epub 2008/10/28).
10. Wiederkehr D, Ogbonnaya A, Casciano R, et al. Clinical impact of early clopidogrel discontinuation following acute myocardial infarction hospitalization or stent implantation: analysis in a nationally representative managed-care population. Curr Med Res Opin. 2009;25(9):2327-34 (Epub 2009/07/29).
11. Boggon R, van Staa TP, Timmis A, et al. Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction - a hospital registry-primary care linked cohort (MINAP-GPRD). Eur Heart J. 2011;32(19):2376-86 (Epub 2011/08/31).
12. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297(2):159-68 (Epub 2006/12/07).
13. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006;113(24):2803-9 (Epub 2006/06/14).
14. Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation. 2007;116(7):745-54 (Epub 2007/08/01).
15. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-15 (Epub 2007/11/06).
16. Hansen L, Chang S. Health research data for the real world: the Thomson Reuters MarketScan Databases. 2011. http://thomsonreuters.com/content/ healthcare/pdf/white-papers/marketscan-white-paper. Accessed 16 Aug 2012.
17. Sorensen R, Gislason GH, Fosbol EL, et al. Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study. Br J Clin Pharmacol. 2008;66(6):875-84 (Epub 2008/10/01).
18. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-9 (Epub 1992/06/01).
19. Pallares MJ, Powers ER, Zwerner PL, et al. Barriers to clopidogrel adherence following placement of drug-eluting stents. Ann Pharmacother. 2009;43(2):259-67 (Epub 2009/02/06).
20. Eaddy MT, Cook CL, O'Day K, et al. How patient cost-sharing trends affect adherence and outcomes: a literature review. P T. 2012;37(1):45-55 (Epub 2012/02/22).
21. Rossini R, Capodanno D, Lettieri C, et al. Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation. Am J Cardiol. 2011;107(2):186-94 (Epub 2011/01/08).
22. Lemesle G, Torguson R, Bonello L, et al. Relation between clopidogrel discontinuation and early cardiovascular events after percutaneous coronary intervention with drug-eluting stents. EuroIntervention. 2011;6(9):1053-9 (Epub 2011/04/27).
23. Gaglia MA Jr, Waksman R. Systematic review of thienopyridine discontinuation and its impact upon clinical outcomes. Eur Heart J. 2011;32(19):2358-64 (Epub 2011/08/02).